Escape from nonsense-mediated decay associates with anti-tumor immunogenicityMore about Open Access at the Crick
Authors listKevin Litchfield James L Reading Emilia Lim Hang Xu Po Liu Maise Al Bakir Yien Ning Sophia Wong Andrew Rowan Samuel A Funt Taha Merghoub David Perkins Martin Lauss Inge Marie Svane Göran Jönsson Javier Herrero James Larkin Sergio A Quezada Matthew D Hellmann Samra Turajlic Charles Swanton
Frameshift insertion/deletions (fs-indels) are an infrequent but highly immunogenic mutation subtype. Although fs-indels are degraded through the nonsense-mediated decay (NMD) pathway, we hypothesise that some fs-indels escape degradation and elicit anti-tumor immune responses. Using allele-specific expression analysis, expressed fs-indels are enriched in genomic positions predicted to escape NMD, and associated with higher protein expression, consistent with degradation escape (NMD-escape). Across four independent melanoma cohorts, NMD-escape mutations are significantly associated with clinical-benefit to checkpoint inhibitor (CPI) therapy (Pmeta = 0.0039). NMD-escape mutations are additionally found to associate with clinical-benefit in the low-TMB setting. Furthermore, in an adoptive cell therapy treated melanoma cohort, NMD-escape mutation count is the most significant biomarker associated with clinical-benefit. Analysis of functional T cell reactivity screens from personalized vaccine studies shows direct evidence of fs-indel derived neoantigens eliciting immune response, particularly those with highly elongated neo open reading frames. NMD-escape fs-indels represent an attractive target for biomarker optimisation and immunotherapy design.
Journal Nature Communications
Issue number 1